Saltar al contenido
Merck

939307

Protein delivery system

Human BDNF, PODS®

Sinónimos:

PODS®

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

NACRES:
NA.21
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

biological source

(Spodoptera frugiperda (Sf9) cell culture)

form

(monodisperse crystals)

packaging

1 ea of 25 μg

technique(s)

: suitable using 3D bioprinting | cell culture

impurities

<0.06 EU/mL Endotoxin

color

colorless

storage temp.

2-8°C

Quality Level

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Protein delivery system, PODS Human BDNF contains the polyhedrin protein co-crystalized with human Brain-derived neurotrophic factor (BDNF) which a protein that plays a crucial role in the growth, development, and maintenance of neurons in the brain. BDNF binds two receptors, the low-affinity nerve growth factor receptor (LNGFR) and the tropomyosin receptor kinase B (TrkB), to support neuron growth and survival. BDNF expression in the hippocampus is essential for long-term memory storage and learning. Some protein domains of BDNF are identical with those of NGF and another neurotrophic factor, designated NT-3 (Neurotrophin-3). Human, mouse, rat, and pig BDNF are cross-reactive.

Application

PODS are composed of a bioactive cargo protein within a polyhedrin crystal lattice, with polyhedrin as the main protein. The 25 µg SKU size indicates the amount of bioactive cargo, typically 0.5% to 5% of the total protein. For instance, a 25 µg SKU at a 2% cargo loading contains 1.25 mg of total protein. PODS enable sustained release of cargo proteins when proteases degrade the polyhedrin scaffold. Growth factors are not bioavailable until released, and their concentration in media depends on the amount added and the release rate. In 10% serum, peak levels are usually reached within 24-48 hours, with about 20% of the cargo becoming soluble.

PODS often require lower concentrations than conventional growth factors, as they maintain effective levels. Pre-incubating with serum or proteases enhances availability, while conventional factors can be added for immediate effects. Optimal amounts should be determined empirically.

Features and Benefits

  • Protein delivery system, PODS Human BDNF comes with molecular weight of 37.6 kDa, length 164 aa, with endotoxin level of <0.06 EU/ml as measured by gel clot LAL assay. PODS co-crystals may be reconstituted at 200 million co-crystals/ml in sterile PBS. 20% glucose has a buoyant density closer to PODS co-crystals and can be useful for aliquoting.
  • This product is produced with no animal derived raw products. All processing and handling employs animal free equipment and animal free protocols. PODS co-crystals are highly stable when stored in aqueous solution (pH range 6 - 8).
  • PODS provides durability, stability AND sustained release, addressing the limitations of conventional and enabling researchers to effortlessly control and manipulate cells in 2D and 3D culture as well as in-vivo.

Legal Information

PODS is a registered trademark of Cell Guidance Systems Ltd

Clase de almacenamiento

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)
Geral C, et al.
Pharmaceutics, 5(1), 127-167 (2013)
Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery
Harris M N, et al.
Pharmacology, Biochemistry, and Behavior, 150-151, 48-56 (2016)
Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities
Liu W, et al.
Neural Plast. (2020)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico